Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity - Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer

Inclusion Criteria

• •Pathologically (histologically or cytologically) confirmed diagnosis of recurrent or second primary head and neck squamous cell carcinoma (HNSCC) in patients with past history of definitive radiation therapy for head and neck cancer. Patients in whom the initial diagnosis was neck metastasis with suspected occult primary in the head and neck will be eligible.
• •Patients with histologic variants such as spindle cell carcinoma, poorly-differentiated keratin positive carcinoma, and lymphoepithelioma will be eligible.
• •* Malignant involvement of 2 or more regional lymph nodes
• •* Extracapsular extension of nodal disease
• •* Microscopically involved mucosal margins of resection (at 5 mM or less)
• •* Perineural involvement
• •* Resected soft tissue disease
• •* Oral cavity or oropharyngeal primaries with nodal disease at levels IV or V
• •Patients must have had prior radiation for head and neck cancer with ≥ 50 % of the recurrent tumor within areas that have been radiated to at least 45 Gy, but not exceeding 72 Gy.
• •Greater than 6 month interval from prior external beam radiation treatment. (Patients who have received intra-operative radiation therapy \[IORT\] within 6 months of registration may be eligible, if there has been no subsequent disease recurrence in the IORT field and criteria for eligibility are otherwise met).
• •KPS \> or = to 70%
• •Age \> or = to 18years
• •Adequate bone marrow function: ANC \> or = to 1,500/μl, platelets \> or = to 100,000/μl, Hgb \> or = to 8 g/dL.
• •Adequate hepatic function.
• •Women of childbearing potential must have a negative pregnancy test.
• •Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least three months thereafter.
• •Patient must sign an informed consent document.